The New York Stock Exchange gave Alere an additional six months to file its 2016 annual report, but it also said it could commence delisting proceedings at any time.
Helicos said it will require "significant additional capital" before the end of the year to fund its operations. The company's "current financial resources raise substantial doubt about its ability to continue as a going concern."
Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.
